Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer Despite ...

Background: CCTG PA.7 (NCT02879318) was a randomized phase II trial comparing gemcitabine (G) and nab-paclitaxel (N) with and without dual immune checkpoint inhibition with durvalumab (D) and ...

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human ...

Patients with advanced melanoma resistant to immune checkpoint or BRAF/MEK inhibitors have treatment options with relatively low efficacy. Lifileucel, a one-time autologous tumor-infiltrating ...

Background: The standard STUPP regimen (radiotherapy with temozolomide [TMZ] followed by adjuvant TMZ) remains limited in efficacy for newly diagnosed glioblastoma (GBM). Anlotinib, a multi-kinase ...

Background: T-DXd is an antibody-drug conjugate approved for advanced HER2+/low/ultra-low breast cancer and multiple other solid tumors. T-DXd carries a rare but serious risk of ILD (incidence 12-15%) ...

Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal ...

Background: ASC, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket, recently received FDA Accelerated Approval for newly diagnosed CML-CP based on major molecular response ...

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors for patients with BRAFV600E-mutated metastatic non-small cell lung cancer: The FRONT-BRAF study. Pooled ...

Background: Trophoblast cell surface antigen 2 (Trop-2), encoded by the transmembrane calcium signal transducer gene, TACSTD2, is highly expressed in many cancers, including endometrial cancer ...

Over 85,000 adolescents and young adults (AYAs; age 15-39 years) are diagnosed with cancer annually in the United States, with nearly 85% expected to become long-term survivors. 1-4 Cancer survivors ...

Background: Adverse drug reactions (ADRs) pose a significant challenge to healthcare systems, leading to 6.5-15% of NHS hospital admissions costing over £2.2 billion annually. Genetic factors play a ...